Progen Industries Ltd (PGLAF) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progen Industries Ltd (PGLAF)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Henrik	5/23/2005 3:46:02 AM
	Read Replies (1) of 349

23 May 2005 PI-88 Phase II First Line Melanoma Trial Launched Based on Encouraging Data. Progen announcement details: progen.com.au --------------------------------------- From RWE Business News: Progen initiates study of anti-cancer drug 11:44, Monday, 23 May 2005 Sydney - Monday - May 23: (RWE Australian Business News) - Cancer drug developer Progen Industries Ltd (ASX: PGL) announced today the initiation of a new Phase II clinical study of its lead anti-cancer product PI-88. The new trial, where PI-88 is combined with chemotherapy agent, DTIC (dacarbazine) will assess PI-88's use as first line treatment for metastatic melanoma. This trial follows on from the encouraging single agent trial results of PI-88 that were announced at the American Society of Clinical Oncology last week. ENDS

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next